Vonda Calcutt, MD
Endocrinology, Diabetes & Metabolism · Walterboro, SCNPI 1477591162
Payments from drug & device makers
Across 790 payments — averaging $465.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$317K
- Johnson & Johnson$25K
- Abbott$18K
- Medtronic$1K
- Lilly USA, LLC$963
- Mannkind Corporation$952
- plus $4K from 21 others
What the payments were for
- Consulting fees$5,6502%
- Speaking & faculty fees$328,11089%
- Travel & lodging$19,2615%
- Food & beverage$14,6944%
- Education$2670%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 350 | $317,291 |
| Johnson & Johnson | 43 | $25,085 |
| Abbott | 73 | $18,500 |
| Medtronic(2 entities) | 30 | $1,266 |
| Lilly USA, LLC | 69 | $963 |
| Mannkind Corporation | 9 | $952 |
| Novo Nordisk | 37 | $606 |
| Amgen(2 entities) | 17 | $430 |
| Insulet Corporation | 19 | $416 |
| Bayer | 20 | $351 |
| Xeris Pharmaceuticals, Inc. | 19 | $309 |
| Corcept Therapeutics | 22 | $308 |
| Dexcom, Inc. | 13 | $294 |
| Sanofi-aventis U.S. LLC | 8 | $208 |
| Boehringer Ingelheim | 11 | $201 |
| Ascendis Pharma Endocrinology Inc | 9 | $154 |
| AbbVie | 10 | $144 |
| BETA Bionics, Inc. | 8 | $108 |
| Merck | 6 | $84 |
| Cequr Corporation | 3 | $80 |
| Tandem Diabetes Care, Inc. | 4 | $63 |
| Recordati_rare_diseases_inc. | 3 | $59 |
| Valeritas, Inc. | 2 | $36 |
| Novartis | 2 | $31 |
| Ascensia Diabetes Care US Inc. | 1 | $15 |
| Madrigal Pharmaceuticals | 1 | $14 |
| Sequel Med Tech, LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$312,841
- INVOKANA$24,330
- FREESTYLE LIBRE 3$17,106
- AFREZZA$850
- MINIMED 780G$350
- TEPEZZA$224
- FreeStyle Libre 2$220
- Omnipod$123
- FreeStyle Libre$113
- TOUJEO$102
How this compares
$367,981 in reported general payments places this provider in the 90th percentile of 99 endocrinology, diabetes & metabolism providers in South Carolina.
See all endocrinology, diabetes & metabolism providers in South Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 309 | $432,801 |
| FarxigaDapagliflozin Propanediol | 250 | $217,937 |
| MounjaroTirzepatide | 144 | $207,420 |
| JardianceEmpagliflozin | 186 | $172,390 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 133 | $172,107 |
| TrulicityDulaglutide | 113 | $147,171 |
| Xigduo XrDapaglifloz Propaned/Metformin | 74 | $99,652 |
| Tresiba Flextouch U-200Insulin Degludec | 64 | $99,246 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 74 | $91,297 |
| JanuviaSitagliptin Phosphate | 101 | $87,943 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 85 | $62,445 |
| Humalog Kwikpen U-200Insulin Lispro | 38 | $60,636 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 71 | $54,617 |
| Tresiba Flextouch U-100Insulin Degludec | 40 | $28,630 |
| Humalog Kwikpen U-100Insulin Lispro | 86 | $28,450 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Fiasp, Novolog | $606 | $458,078358 claims |
| Lilly USA, LLCMounjaro, Trulicity, Lyumjev, Humalog, Humalog Mix 75-25 | $963 | $394,290345 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $201 | $234,835271 claims |
| AstraZenecaFarxiga | $317,291 | $217,937250 claims |
| MerckJanuvia, Janumet Xr | $84 | $142,560172 claims |
| Johnson & JohnsonInvokana | $25,085 | $26,79723 claims |
| AbbVieSynthroid | $144 | $8,040118 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 99 endocrinology, diabetes & metabolism providers in South Carolina.
Other endocrinology, diabetes & metabolism in Walterboro
- Ronald MayfieldSpartanburg$8.9M
- Donald EagertonMyrtle Beach$7.9M
- Beatrice HullCharleston$987K
- Anne LarochelleMyrtle Beach$678K
- Gauri DhirMyrtle Beach$417K
- Cory WhiteGreenville$413K
- Louis HaenelCharleston$377K
- Kathie HermayerCharleston$337K
- Ray VaughtersAiken$321K
- Joseph MathewsSummerville$297K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.